Anti-cancer effects of Tranilast: An update.

Tranilast (TRN) or (N-3,4 -dimethoxy cinnamoyl]-anthranilic acid) is an analog of a tryptophan metabolite and is identified mainly as an anti-allergic agent with limited side effects. The anti-cancer effects of tranilast either alone or in combination with chemotherapeutic drugs have been evidenced in several pre-clinical studies. The main mechanism of action of tranilast includes targeting and modulation of various signaling and immune regulatory pathways including Transforming growth factor-beta (TGF-β), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), phosphatidylinositol 3-kinase (PI3K), MAP-Kinase (MAPK), Protein kinase B (‎Akt/PKB), c-Jun N-terminal kinase, modulation of cancer stem cells, etc. Most of these pathways are involved in tumor proliferation, invasion, and metastasis and it is postulated that tranilast, with its low toxicity profile and high anti-carcinogenic abilities, can serve as a potential anti-tumorigenic agent. The main aim of this review is to provide updated information on the anti-cancer effects of tranilast and its significance as a therapeutic agent.

• Publication year

  2021

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  2021-06-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.biopha.2021.111844PMID 34174504
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of transforming growth factor-beta by Tranilast reduces tumor growth and ameliorates fibrosis in colorectal cancer

  2021cited by this paper
• Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

  2021cited by this paper
• Synthetic Lethality Screening Identifies FDA-Approved Drugs that Overcome ATP7B-Mediated Tolerance of Tumor Cells to Cisplatin

  2020cited by this paper
• Cancer-associated fibroblasts promote the survival of irradiated nasopharyngeal carcinoma cells via the NF-κB pathway

  2020cited by this paper
• Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano‐immunotherapy in Breast Cancer Lung Metastasis

  2020cited by this paper
• Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts

  2020cited by this paper
• Tranilast Inhibits TGF-β1–induced Epithelial-mesenchymal Transition and Invasion/Metastasis via the Suppression of Smad4 in Human Lung Cancer Cell Lines

  2020cited by this paper
• Discovering the anticancer potential of non-oncology drugs by systematic viability profiling

  2020cited by this paper
• TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity

  2020cited by this paper
• Tranilast enhances the effect of anticancer agents in osteosarcoma

  2019cited by this paper
• Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation

  2019cited by this paper
• Smart cancer nanomedicine

  2019cited by this paper
• Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy.

  2019cited by this paper
• Esophageal cancer stem cells are suppressed by tranilast, a TRPV2 channel inhibitor

  2018cited by this paper
• Increased immune cell infiltration in patient-derived tumor explants treated with Traniplatin: an original Pt(iv) pro-drug based on Cisplatin and Tranilast.

  2018cited by this paper
• Teucrium polium Extract Enhances the Anti-Angiogenesis Effect of Tranilast on Human Umbilical Vein Endothelial Cells

  2018cited by this paper
• Tranilast inhibits the expression of genes related to epithelial-mesenchymal transition and angiogenesis in neurofibromin-deficient cells

  2018cited by this paper
• Prior anti-CAFs break down the CAFs barrier and improve accumulation of docetaxel micelles in tumor

  2018cited by this paper
• TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure

  2018cited by this paper
• Importance of human peritoneal mesothelial cells in the progression, fibrosis, and control of gastric cancer: inhibition of growth and fibrosis by tranilast

  2017cited by this paper
• Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner

  2017cited by this paper
• Concise Review: Emerging Drugs Targeting Epithelial Cancer Stem‐Like Cells

  2017cited by this paper
• Transforming growth factor-β: A therapeutic target for cancer

  2017cited by this paper
• The Different Mechanisms of Cancer Drug Resistance: A Brief Review

  2017cited by this paper
• Programmed death‐ligand 1 expression at tumor invasive front is associated with epithelial‐mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma

  2017cited by this paper
• Anti-angiogenic drugs: direct anti-cancer agents with mitochondrial mechanisms of action

  2017cited by this paper
• Using Affinity To Provide Long-Term Delivery of Antiangiogenic Drugs in Cancer Therapy.

  2017cited by this paper
• The tryptophan derivative, tranilast, and conditioned medium with indoleamine 2,3-dioxygenase-expressing cells inhibit the proliferation of lymphoid malignancies.

  2015cited by this paper
• Targeting mitochondria metabolism for cancer therapy.

  2015cited by this paper
• Tranilast: a review of its therapeutic applications.

  2015cited by this paper
• Tranilast Inhibits the Function of Cancer‐Associated Fibroblasts Responsible for the Induction of Immune Suppressor Cell Types

  2014cited by this paper
• Regulation of the anti-tumour immune response by cancer-associated fibroblasts.

  2014cited by this paper
• A Pilot Study of Scheduled Endoscopic Balloon Dilation With Oral Agent Tranilast to Improve the Efficacy of Stricture Dilation After Endoscopic Submucosal Dissection of the Esophagus

  2012cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Breast Cancer Stem-Like Cells Are Inhibited by a Non-Toxic Aryl Hydrocarbon Receptor Agonist

  2010cited by this paper
• Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer

  2010cited by this paper
• Tranilast suppresses prostate cancer growth and osteoclast differentiation in vivo and in vitro

  2010cited by this paper
• Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor β1‐associated osteoblastic changes

  2009cited by this paper
• Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.

  2009cited by this paper
• Tranilast inhibits the growth and metastasis of mammary carcinoma

  2009cited by this paper
• The potential role of Akt phosphorylation in human cancers.

  2008cited by this paper
• Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes.

  2008cited by this paper
• Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations

  2007cited by this paper
• Nanocarriers as an emerging platform for cancer therapy.

  2007cited by this paper
• Angiogenesis in Cancer

  2006cited by this paper
• Cancer: Inflammation by remote control

  2005cited by this paper
• Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite

  2005cited by this paper
• Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21(waf1) and p53.

  2002cited by this paper
• Anti-tumor effect of N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) on experimental pancreatic cancer.

  2002cited by this paper
• N‐[3,4‐dimethoxycinnamoyl]‐anthranilic acid (tranilast) inhibits transforming growth factor‐β release and reduces migration and invasiveness of human malignant glioma cells

  2001cited by this paper
• Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo

  1997cited by this paper
• A Double Blind Controlled Trial of N‐(3′, 4′‐Dimethoxycinnamoyl) Anthranilic Acid on Children with Bronchial Asthma

  1979cited by this paper

• Inhibition of the NLRP3 pathway as a strategy for SLE therapy.

  2026cites this paper
• Efficacy and safety of tranilast combined with minocycline in the treatment of moderate-to-severe rosacea: a prospective, randomized controlled study.

  2025cites this paper
• PET imaging-guided biomimetic nanoplatform reprograms the tumor immune microenvironment and disrupts stromal barriers to potentiate immunotherapy in malignancy

  2025cites this paper
• Drug Repurposing in Oncology: A Strategic Pathway to Unlocking New Therapeutic Potential

  2025cites this paper
• Tranilast inhibits cell proliferation, migration and invasion of human hypertrophic scar fibroblasts by NOP2-mediated m5C methylation on COL1A1.

  2025cites this paper
• Trimethylsilyl ester of N-acetylanthranilic acid: synthesis, characterization, reactivity

  2025cites this paper
• Exploring the anticancer potential of nitrated N-substituted-4-hydroxy-2-quinolone-3-carboxamides: synthesis, biological assessment, and computational analysis

  2025influential citation
• TGF-β1-mediated downregulation of L1CAM in pancreatic ductal adenocarcinoma drives upregulation of collagen 17A1 and MMP2, facilitating tumor invasiveness and metastasis

  2025cites this paper
• Late-Stage Aryl C-H Bond Carboxylation with CO2 via Combining Metal-Free C-H Bond Borylation and ZnEt2-Promoted C-B Bond Carboxylation.

  2025cites this paper
• Combating breast cancer-associated metastasis using paclitaxel and tranilast-loaded human serum albumin nanoparticles

  2025cites this paper
• The AHR-NRF2-JDP2 gene battery: Ligand-induced AHR transcriptional activation.

  2025cites this paper
• Smart on-demand drug release strategies for cancer combination therapy.

  2025cites this paper
• An Ultrasound‐Responsive and In Situ Gelling Hydrogel Nanocomposite for Boosting Anti PD‐L1 Immunotherapy via Remodeling Aberrant ECM of Post‐Surgical Residual Cancer

  2024cites this paper
• Improving the Efficacy of Common Cancer Treatments via Targeted Therapeutics towards the Tumour and Its Microenvironment

  2024cites this paper
• Protective effects of naringin against oxaliplatin-induced testicular damage in rats: Involvement of oxidative stress, inflammation, endoplasmic reticulum stress, apoptosis, and histopathology

  2024cites this paper
• Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit.

  2024cites this paper
• Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy.

  2024cites this paper
• Tranilast alleviates skin inflammation and fibrosis in rosacea-like mice induced by long-term exposure to LL-37.

  2024cites this paper
• The multifaceted role of the stroma in the healthy prostate and prostate cancer

  2024cites this paper
• Single‐cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis

  2024cites this paper
• Iron-Catalyzed Cross-Dehydrogenative Coupling of para-Quinone Methides with Formamides: In Situ Activation of C(sp2)-H Bonds.

  2024cites this paper
• Tranilast-matrine co-amorphous system: Strong intermolecular interactions, improved solubility, and physiochemical stability.

  2023cites this paper
• Non-canonical two-step biosynthesis of anti-oomycete indole alkaloids in Kickxellales

  2023cites this paper
• Current landscape of miRNAs and TGF-β signaling in lung cancer progression and therapeutic targets.

  2023cites this paper
• The First AAU International Conference on Pharmacy and Biomedical Sciences

  2023cites this paper
• The ‘speck’-tacular oversight of the NLRP3-pyroptosis pathway on gastrointestinal inflammatory diseases and tumorigenesis

  2023cites this paper
• Pharmacological Therapy of Proliferative Vitreoretinopathy: Systematic In Vitro Comparison of 36 Pharmacological Agents

  2023cites this paper
• Mechanism of anti-hyperuricemia of isobavachin based on network pharmacology and molecular docking

  2023cites this paper
• Role of the NLRP3 inflammasome in gynecological disease.

  2023cites this paper
• Strategy of targeting the tumor microenvironment via inhibition of fibroblast/fibrosis remodeling new era to cancer chemo-immunotherapy resistance.

  2023cites this paper
• Activated fibroblasts in cardiac and cancer fibrosis: An overview of analogies and new potential therapeutic options.

  2023cites this paper
• Tranilast reduces cardiomyocyte injury induced by ischemia‑reperfusion via Nrf2/HO‑1/NF‑κB signaling

  2023cites this paper
• Repurposing FDA-approved drugs against the toxicity of platinum-based anticancer drugs.

  2022cites this paper
• A Space‐Time Conversion Vehicle for Programmed Multi‐Drugs Delivery into Pancreatic Tumor to Overcome Matrix and Reflux Barriers

  2022cites this paper
• The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets

  2022cites this paper
• pH-sensitive bovine serum albumin nanoparticles for paclitaxel delivery and controlled release to cervical cancer

  2022cites this paper
• Mild Copper-Catalyzed, l-Proline-Promoted Cross-Coupling of Methyl 3-Amino-1-benzothiophene-2-carboxylate

  2021cites this paper
• Computationally repurposing drugs for breast cancer subtypes using a network-based approach

  2021cites this paper